RWE Market Impact on Medicines: A Lens for Pharma
IMS Health has developed the most comprehensive view of Real-World Evidence use and supply published to date. To learn how this could reshape your company's approach to evidence, click here
Pricing & Market Access Outlook: 2012: Join our senior team as they share their perspectives on the key issues in IMSCG’s annual state of play in pricing and market access
New Paradigm - Incorporating Access Decisions Into Portfolio Strategy: Our Portfolio Strategy leadership presented this framework for value-based access strategy decisions at the recent 12th Annual Portfolio and Project Management for Pharma Conference in Barcelona.
Model Behaviour: IMSCG Principals Steven Flostrand and Raja Shankar look at the consequences of healthcare reforms across Europe, and identify how companies can successfully manage the new and more challenging healthcare funding environment.
The Big Sell: Biologics In Emerging Markets This paper published in Pharmaceutical Executive looks at the complex opportunities and access challenges that face commercialization of biologics in Africa, Asia, and Latin America.
Supercharge your career in life sciences consulting.
Our insights are your competitive advantage.
IMS Consulting Group is the world’s leading, specialized advisor on critical business issues in life sciences.
With a global presence and local expertise across five continents, we know the pulse of the market – anticipating change, understanding its impact and resolving the challenges it brings. From pricing and market access and marketing issues to product, portfolio and geographic investment decisions – our life sciences consulting teams offer insights that drive results. All backed by the strongest evidence and analytics.
Pharma growth rates will be the lowest ever through 2014. What questions should you address?
'Prove it works' is now the new era. How to provide the evidence required to engage healthcare stakeholders?